节点文献

恩度联合GP方案治疗晚期NSCLC的近期疗效

Short-term Efficacy of YH-16 Combined with GP Regimen for Advanced Non-small Cell Lung Cancer

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 陈群谢强石琴肖松

【Author】 CHEN Qun1,XIE Qiang1,SHI Qin1,XIAO Song21.Department of Tumour,Fuzhou Pulmonary Hospital of Fujian Medical College Teaching Hospital,Fuzhou 350008,China;2.Deparment of Medical,The Han Jiang Hospital

【机构】 福建医科大学教学医院福州肺科医院肿瘤科福建省莆田市涵江医院内科

【摘要】 目的观察恩度(重组人血管内皮抑素,YH-16)联合GP方案(吉西他滨+顺铂)治疗晚期非小细胞肺癌的近期临床疗效,评价恩度临床应用的安全性和耐受性。方法 GP+YH-16(治疗组)和GP(对照组)方案化疗两周期。结果治疗组客观有效率为45.5%,疾病控制率为90.9%,症状缓解率为81.8%,生活质量改善率为63.6%;对照组分别为34.3%,71.4%,60.0%,40.0%;除客观有效率比较差异无统计学意义外(P>0.05),其余指标比较差异均有统计学意义(P<0.05)。不良反应多数是1/2级,主要与化疗有关,治疗组出现4例心悸和心率失常。结论恩度与GP方案联合应用,能提高晚期NSCLC的疾病控制率,能在一定程度上缓解弥漫性肺小结节转移灶和浆膜腔积液,从而改善肺功能和生活质量,且安全性较好。

【Abstract】 Objective To investigate the short-term efficacy and toxicity of YH-16 combined with GP regimen for NSCLC.Methods The patients were divided into GP + YH-16(trial group) and GP(control group),and the efficacy and toxicity were evaluated after 2 cycles according to RECIST criteria.Results The trial group’s effective rate was 45.5% while the control group was 34.3%,P>0.05.For three other results:the disease control rate symptomatic relief rate and QOL improvement rate,they were 90.9%,81.8% and 63.6% in the trial group and 71.4%,60.0% and 40.0% in the control group respectively,P<0.05.Side effects were almostly grade 1/2 and concened with chemotherapy.4 patients in the trial group suffered cardiopalmus and arrhythmias.Conclusion The combination of YH-16 with GP regimen could improve the disease control rate of advanced NSCLC obviously,relieving metastasis focus of tumor,reducing the serous pleural effusion,improving lung function.Besides,side effects was less than those of others.

  • 【文献出处】 肿瘤防治研究 ,Cancer Research on Prevention and Treatment , 编辑部邮箱 ,2011年02期
  • 【分类号】R734.2
  • 【被引频次】12
  • 【下载频次】198
节点文献中: 

本文链接的文献网络图示:

本文的引文网络